A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Protocol # AstraZeneca D702FC00001
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Salvatore Del Prete, MD
Sponsor(s)
AstraZeneca
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879
Stamford, CT 06902
Main: 203-358-8879